A Multicentre , Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (Tectin) for Moderate to Severe Inadequately Controlled Cancer-Related Pain.

Trial Profile

A Multicentre , Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (Tectin) for Moderate to Severe Inadequately Controlled Cancer-Related Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2014

At a glance

  • Drugs Tetrodotoxin (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00725114).
    • 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00725114).
    • 09 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT00725114).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top